Ikarian Capital, LLC Verastem, Inc. Transaction History

Ikarian Capital, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$1.02 - $1.83 $459,000 - $823,500	-450,000 Reduced 66.37%	228,023 $265,000
Q1 2022 May 13, 2022	BUY	$1.06 - $2.1 $43,091 - $85,369	40,652 Added 6.38%	678,023 $956,000
Q4 2021 Feb 14, 2022	SELL	$2.05 - $3.2 $1.21 Million - $1.89 Million	-590,000 Reduced 48.07%	637,371 $1.31 Million
Q3 2021 Nov 15, 2021	SELL	$2.54 - $4.07 $424,238 - $679,783	-167,023 Reduced 11.98%	1,227,371 $3.78 Million
Q2 2021 Aug 16, 2021	SELL	$2.57 - $4.85 $3.34 Million - $6.31 Million	-1,300,000 Reduced 48.25%	1,394,394 $5.68 Million
Q1 2021 May 17, 2021	BUY	$1.9 - $2.82 $835,625 - $1.24 Million	439,803 Added 19.51%	2,694,394 $6.66 Million
Q4 2020 Feb 12, 2021	BUY	$1.15 - $2.4 $967,453 - $2.02 Million	841,264 Added 59.52%	2,254,591 $4.8 Million
Q3 2020 Nov 16, 2020	SELL	$1.11 - $1.68 $555,000 - $840,000	-500,000 Reduced 26.13%	1,413,327 $1.71 Million
Q2 2020 Aug 14, 2020	SELL	$1.69 - $4.2 $5.64 Million - $14 Million	-3,339,100 Reduced 63.57%	1,913,327 $3.29 Million
Q1 2020 May 15, 2020	BUY	$1.26 - $3.38 $6.62 Million - $17.8 Million	5,252,427 New	5,252,427 $13.9 Million

297K

Ticker VSTM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 210,000,000
Market Cap $1.09B
Description
Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylat...

Get notified when there are updates to the investment portfolio of Ikarian Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Ikarian Capital, LLC with notifications on news.